Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,653 across all filing types
Latest filing 2023-04-23 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
2022年年度报告
Annual Report Classification · 100% confidence The document is titled "贝达药业股份有限公司 2022 年年度报告全文" which translates to "Betta Pharmaceuticals Co., Ltd. 2022 Annual Report Full Text." It contains detailed sections typical of an annual report, including company overview, financial data, management discussion and analysis, corporate governance, environmental and social responsibility, shareholder information, and full financial statements. The document covers the full fiscal year 2022 (January 1 to December 31, 2022) and includes comprehensive financial metrics, business descriptions, industry analysis, and future outlook. The length is substantial (15,000 characters), and it is not a brief announcement or a certification. Therefore, it fits the definition of an Annual Report (10-K). FY 2022
2023-04-23 Chinese
2022年年度财务报告
Annual Report Classification · 100% confidence The document is titled "贝达药业股份有限公司 2022 年年度财务报告" which translates to "Betta Pharmaceuticals Co., Ltd. 2022 Annual Financial Report." It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and notes. It also includes an audit report with an unqualified opinion dated April 21, 2023, issued by a registered accounting firm. The content is comprehensive, covering the full fiscal year 2022, with detailed financial data and management responsibilities. This matches the definition of an Annual Report (10-K) which is an official yearly report covering company activity and full financial performance. The document length is 15,000 characters, indicating it is the full report, not just an announcement or summary. Therefore, the correct classification is Annual Report (10-K). FY 2022
2023-04-23 Chinese
贝达药业股份有限公司章程（2023年4月）
Governance Information Classification · 100% confidence The document is titled as the Articles of Association (章程) of 贝达药业股份有限公司 (Betta Pharmaceuticals Co. Ltd.) dated April 2023. It contains detailed provisions about the company's organization, shareholder rights, board structure, share issuance, share transfer, shareholder meetings, and other governance matters. The content is legal and governance-related, focusing on the company's internal rules and regulations rather than financial performance or announcements. There is no indication of financial statements, audit reports, earnings data, or meeting results. The document is lengthy (15,000 characters) and is a full text of the company's Articles of Association, which is a governance document. Therefore, the appropriate classification is Governance Information (CGR).
2023-04-23 Chinese
2022年度独立董事述职报告（汪炜）
Board/Management Information Classification · 95% confidence The document is titled '2022 年度独立董事述职报告' which translates to '2022 Annual Independent Director's Work Report'. It details the independent director's attendance at board meetings, committee meetings, shareholder meetings, independent opinions on various company matters, on-site investigations, and efforts to protect investor rights. The content focuses on the independent director's duties, opinions, and activities during the year 2022. It is not a full annual report, audit report, or financial statement, but rather a management-related report focusing on board and governance activities. This fits best under 'Board/Management Information (MANG)' which covers announcements of changes or reports related to the company's board or senior management. The document is over 6000 characters and contains substantive content, not just an announcement or certification, so it is not RPA or RNS. Therefore, the classification is MANG with high confidence.
2023-04-23 Chinese
独立董事关于第四届董事会第三次会议相关事项的事前认可意见
Audit Report / Information Classification · 95% confidence The document is a statement from independent directors regarding their prior approval opinion on the proposal to reappoint the accounting firm for the 2023 audit. It references regulatory rules related to independent directors and audit firms, and it is dated April 14, 2023. The content is about the audit firm appointment and does not contain actual financial statements or audit results. It is not a full audit report but rather an opinion related to audit firm reappointment. The document length is short (742 characters), and it is a formal approval opinion by independent directors, which aligns with Audit Report / Information filings that include audit-related opinions and confirmations but are not full annual reports. Therefore, the best classification is Audit Report / Information (AR). FY 2023
2023-04-23 Chinese
2022年度募集资金年度存放与使用情况专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2022年度募集资金存放与使用情况专项报告" which translates to "2022 Annual Special Report on the Deposit and Use of Raised Funds". It details the amounts of funds raised through stock issuance, their deposit, usage, management, and changes in investment projects related to the raised funds. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and includes detailed financial tables and explanations about the use and management of the raised capital. The document is a specialized report focused on the management and use of capital raised by the company, not a general annual report or earnings release. It is not a simple announcement or certification but a substantive report on fundraising capital usage. This matches the description of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. Therefore, the document should be classified as CAP.
2023-04-23 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.